Phathom Pharmaceuticals Announces Pricing of Initial Public Offering
BUFFALO GROVE, Ill.–(BUSINESS WIRE)–Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today it has priced its initial public offering of 9,563,157 shares of its common stock at a public…
News story published on 2019-10-25T04:14:00.0000000Z
